{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=39",
    "query": {
      "intervention": "serum sample",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 8372,
    "total_pages": 838,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T02:13:13.047Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00730717",
      "title": "Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pyoderma Gangrenosum"
      ],
      "interventions": [
        {
          "name": "Humira",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wright State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-05",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730717"
    },
    {
      "nct_id": "NCT01799317",
      "title": "How Bone is Made in Children Receiving Dialysis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bone Mineralization Defect"
      ],
      "interventions": [
        {
          "name": "Vitamin D2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "6 Years to 21 Years"
      },
      "enrollment_count": 60,
      "start_date": "2009-03",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2013-02-26",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 2,
      "location_summary": "Loma Linda, California • Los Angeles, California",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01799317"
    },
    {
      "nct_id": "NCT03501979",
      "title": "Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Leptomeningeal Disease"
      ],
      "interventions": [
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2019-02-20",
      "completion_date": "2021-06-22",
      "has_results": true,
      "last_update_posted_date": "2025-08-29",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03501979"
    },
    {
      "nct_id": "NCT00685061",
      "title": "Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplantation"
      ],
      "interventions": [
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Campath-1H",
          "type": "DRUG"
        },
        {
          "name": "Daclizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2002-11",
      "completion_date": "2005-09",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00685061"
    },
    {
      "nct_id": "NCT00022048",
      "title": "Bevacizumab in Treating Patients With Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-08",
      "completion_date": "2004-11",
      "has_results": false,
      "last_update_posted_date": "2013-05-15",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 3,
      "location_summary": "Tucson, Arizona • Stanford, California • Houston, Texas",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022048"
    },
    {
      "nct_id": "NCT03366155",
      "title": "Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Liver Metastases",
        "Colorectal Adenocarcinoma",
        "Colorectal Cancer With Hepatic Metastases",
        "Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Codman 3000 constant flow pump catheter",
          "type": "DEVICE"
        },
        {
          "name": "Panitumumab",
          "type": "DRUG"
        },
        {
          "name": "FUDR-Dex",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "5FU",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "HAIP installation",
          "type": "PROCEDURE"
        },
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "Medtronic SynchroMed II Pump",
          "type": "DEVICE"
        },
        {
          "name": "Floxuridine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT C/A/P",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT Angiogram (abdomen)",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Tumor and normal liver biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-06-24",
      "completion_date": "2025-11-13",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03366155"
    },
    {
      "nct_id": "NCT00760435",
      "title": "Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kawasaki Disease"
      ],
      "interventions": [
        {
          "name": "Infliximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Weeks",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Weeks to 17 Years"
      },
      "enrollment_count": 196,
      "start_date": "2009-03",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2014-11-24",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 2,
      "location_summary": "La Jolla, California • Columbus, Ohio",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00760435"
    },
    {
      "nct_id": "NCT00527735",
      "title": "Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Small Cell Lung Cancer",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 334,
      "start_date": "2008-02",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 27,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00527735"
    },
    {
      "nct_id": "NCT04745910",
      "title": "Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Tumor Lysis Syndrome"
      ],
      "interventions": [
        {
          "name": "Pegloticase",
          "type": "DRUG"
        },
        {
          "name": "Rasburicase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2022-04-05",
      "completion_date": "2026-04-27",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04745910"
    },
    {
      "nct_id": "NCT05388123",
      "title": "Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hairy Cell Leukemia"
      ],
      "interventions": [
        {
          "name": "Low dose vemurafenib plus rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scripps Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 15,
      "start_date": "2022-03-02",
      "completion_date": "2026-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-10-21T02:13:13.047Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05388123"
    }
  ]
}